Re Francesca, Staudacher Carlo, Zamai Loris, Vecchio Viviana, Bregni Marco
Department of Oncology, Scientific Institute San Raffaele, Milan, Italy.
Cancer. 2006 Aug 1;107(3):640-8. doi: 10.1002/cncr.22002.
BACKGROUND: Donor alloreactive natural killer (NK) cells have a potent antileukemic effect in haploidentical stem cell transplantation. Whether alloreactive NK cells are able to specifically kill fresh tumor cells from primary solid tumors was analyzed. METHODS: NK cells were purified from healthy donors for the expression of inhibitory killer cell immunoglobulin (Ig)-like receptors (KIRs), ex vivo expanded, and used as effector cells. Their cytotoxic effect on tumor cells freshly obtained from surgical specimens was assessed by means of a single-cell cytotoxic assay (SCCA). RESULTS: Tumor cells from 1 ovarian, 1 gastric, 3 colon, and 4 renal cell cancers were analyzed and found susceptible to alloreactive NK cell killing (>20% lysis at an effector cell to target cell [E:T] ratio of 10:1 for tumor cells not expressing at least 1 human lymphocyte antigen [HLA] class I KIR-ligand group). Remarkably, NK cells that recognized specific HLA-C group mismatches were able to kill HLA-C KIR ligand-mismatched tumor cells, whereas no lysis of target cells occurred with KIR ligand-matched tumor targets. CONCLUSIONS: Alloreactive NK-cell mediated antitumor effects might provide useful insights for designing new cell therapy approaches against solid tumors.
Semin Cancer Biol. 2006-10
J Immunol. 2009-10-1
Biol Blood Marrow Transplant. 2006-8
Int J Hematol Oncol Stem Cell Res. 2024-4-1
Cancers (Basel). 2021-4-16
Curr Oncol. 2021-2-26
Front Immunol. 2019-1-21